CD274 and gastric cancer: Therefore, it is still unclear whether the efficacy and survival advantage of gastric cancer immunotherapy increase with increasing PD-L1 expression levels, and the use of PD-L1 alone as a biomarker to predict immunotherapy efficacy is not accurate.